Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been assigned an average rating of “Moderate Buy” from the fifteen brokerages that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $77.93.

APLS has been the subject of several research analyst reports. The Goldman Sachs Group increased their price objective on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, January 9th. Mizuho reissued a “neutral” rating and issued a $60.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Robert W. Baird reissued an “outperform” rating and issued a $81.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, February 6th. Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price target for the stock from $68.00 to $80.00 in a research note on Monday, February 5th. Finally, Oppenheimer raised their price target on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 30th.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $58.66, for a total value of $234,640.00. Following the sale, the chief financial officer now owns 93,338 shares of the company’s stock, valued at approximately $5,475,207.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders have sold 406,651 shares of company stock valued at $25,130,257 in the last 90 days. 7.50% of the stock is currently owned by insiders.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. First Horizon Advisors Inc. grew its holdings in shares of Apellis Pharmaceuticals by 69.0% during the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after purchasing an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 1st quarter worth approximately $29,000. Covestor Ltd grew its holdings in shares of Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after purchasing an additional 677 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $38,000. Finally, US Bancorp DE grew its holdings in shares of Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after purchasing an additional 884 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Trading Up 0.0 %

NASDAQ:APLS opened at $47.53 on Monday. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals has a 1-year low of $19.83 and a 1-year high of $94.75. The firm has a market capitalization of $5.73 billion, a price-to-earnings ratio of -10.61 and a beta of 0.88. The stock has a fifty day simple moving average of $59.71 and a 200 day simple moving average of $57.04.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73). The firm had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The business’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same period in the prior year, the business earned ($1.50) EPS. Sell-side analysts forecast that Apellis Pharmaceuticals will post -1.33 earnings per share for the current year.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).